OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,507,442 to OncoMed for methods of treating cancer with its antibody vantictumab (OMP-18R5). Vantictumab targets and inhibits the Wnt pathway, which is believed to be an important CSC pathway. The patent expires in 2029.
Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
Targeted Medical Pharma, Inc., announced that the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia of chronic disease.
First patient treated in groundbreaking stem cell therapy trial for heart attack
Canadian researchers have treated the first patient in a world-first clinical trial using genetically enhanced stem cells to repair damaged heart muscle after a major heart attack. The formal name of the trial is ENACT-AMI, which stands for "Enhanced Angiogenic Cell Therapy – Acute Myocardial Infarction.”
Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
Adaptive Biotechnologies announced that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient’s adaptive immune system to fight infection after a cord blood transplant.
Celator®pharmaceuticals announces start of clinical study in patients with untreated myelodysplastic syndrome (MDS) or acute myeloid leukemia at high risk of treatment-related mortality
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection in patients with untreated high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), excluding acute promyelocytic leukemia, at high risk of treatment-related mortality.
Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration
Gamida Cell announced that the first patient has been successfully transplanted in the company’s second Phase I/II study of NiCord®, as an alternative, experimental treatment for blood cancers. The transplant took place at Duke University Medical Center. Of great significance: This is the first study researching the outcome of a whole umbilical cord blood unit (UCBU) expanded in culture and transplanted in myeloablated patients without the support of un-manipulated stem cells derived from a second UCBU.
Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia
Boehringer Ingelheim announced that the FDA has granted a Breakthrough Therapy designation to volasertib*, a selective and potent polo-like kinase (Plk) inhibitor, for the treatment of patients with AML.
Factor Bioscience Granted First U.S. Patent for RNA‐Based Reprogramming Technology
The United States Patent and Trademark Office today granted Factor Bioscience the first patent covering methods for reprogramming cells using RNA, a technology with wide‐ranging applications in biological research and personalized medicine. The patented methods can transform patient skin cells into stem cells more rapidly, efficiently, and safely than previous techniques.